Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 115

Similar articles for PubMed (Select 23395836)

1.

Bone loss associated with hyperprolactinemia in patients with schizophrenia.

Kinon BJ, Liu-Seifert H, Stauffer VL, Jacob J.

Clin Schizophr Relat Psychoses. 2013 Oct;7(3):115-23. doi: 10.3371/CSRP.KISE.020113.

PMID:
23395836
2.

Prevalence of hyperprolactinemia in schizophrenic patients treated with conventional antipsychotic medications or risperidone.

Kinon BJ, Gilmore JA, Liu H, Halbreich UM.

Psychoneuroendocrinology. 2003 Apr;28 Suppl 2:55-68.

PMID:
12650681
3.

Second-generation antipsychotics and bone turnover in schizophrenia.

Okita K, Kanahara N, Nishimura M, Yoshida T, Yasui-Furukori N, Niitsu T, Yoshida T, Ishikawa M, Kimura H, Nomura F, Iyo M.

Schizophr Res. 2014 Aug;157(1-3):137-41. doi: 10.1016/j.schres.2014.05.009. Epub 2014 Jun 2.

PMID:
24888527
4.

Bone remodeling, bone mass and weight gain in patients with stabilized schizophrenia in real-life conditions treated with long-acting injectable risperidone.

Doknic M, Maric NP, Britvic D, Pekic S, Damjanovic A, Miljic D, Stojanovic M, Radojicic Z, Jasovic Gasic M, Popovic V.

Neuroendocrinology. 2011;94(3):246-54. doi: 10.1159/000329391. Epub 2011 Oct 7.

PMID:
21986470
5.

Improvement in hyperprolactinemia and reproductive comorbidities in patients with schizophrenia switched from conventional antipsychotics or risperidone to olanzapine.

Kinon BJ, Ahl J, Liu-Seifert H, Maguire GA.

Psychoneuroendocrinology. 2006 Jun;31(5):577-88. Epub 2006 Feb 20.

PMID:
16488084
6.

Antipsychotic-induced hyperprolactinemia inhibits the hypothalamo-pituitary-gonadal axis and reduces bone mineral density in male patients with schizophrenia.

Kishimoto T, Watanabe K, Shimada N, Makita K, Yagi G, Kashima H.

J Clin Psychiatry. 2008 Mar;69(3):385-91.

PMID:
18278991
7.

A cross-sectional evaluation of the effect of risperidone and selective serotonin reuptake inhibitors on bone mineral density in boys.

Calarge CA, Zimmerman B, Xie D, Kuperman S, Schlechte JA.

J Clin Psychiatry. 2010 Mar;71(3):338-47. doi: 10.4088/JCP.08m04595gre.

8.

Antipsychotic drugs: a new risk factor for osteoporosis in young women with schizophrenia?

O'Keane V, Meaney AM.

J Clin Psychopharmacol. 2005 Feb;25(1):26-31.

PMID:
15643097
9.

[Antipsychotic-drug-induced hyperprolactinemia: physiopathology, clinical features and guidance].

Besnard I, Auclair V, Callery G, Gabriel-Bordenave C, Roberge C.

Encephale. 2014 Feb;40(1):86-94. doi: 10.1016/j.encep.2012.03.002. Epub 2013 Aug 5. Review. French.

PMID:
23928066
10.

Effects of elevated serum prolactin on bone mineral density and bone metabolism in female patients with schizophrenia: a prospective study.

Abraham G, Paing WW, Kaminski J, Joseph A, Kohegyi E, Josiassen RC.

Am J Psychiatry. 2003 Sep;160(9):1618-20.

PMID:
12944336
11.

Effects of long-term prolactin-raising antipsychotic medication on bone mineral density in patients with schizophrenia.

Meaney AM, Smith S, Howes OD, O'Brien M, Murray RM, O'Keane V.

Br J Psychiatry. 2004 Jun;184:503-8.

12.

Antipsychotic-induced hyperprolactinaemia: mechanisms, clinical features and management.

Haddad PM, Wieck A.

Drugs. 2004;64(20):2291-314. Review.

PMID:
15456328
13.

Hyperprolactinemia and bone mineral density: the potential impact of antipsychotic agents.

Naidoo U, Goff DC, Klibanski A.

Psychoneuroendocrinology. 2003 Apr;28 Suppl 2:97-108. Review.

PMID:
12650684
14.

Effects of aripiprazole on prolactin levels in subjects with schizophrenia during cross-titration with risperidone or olanzapine: analysis of a randomized, open-label study.

Byerly MJ, Marcus RN, Tran QV, Eudicone JM, Whitehead R, Baker RA.

Schizophr Res. 2009 Feb;107(2-3):218-22. doi: 10.1016/j.schres.2008.09.019. Epub 2008 Nov 26.

PMID:
19038534
15.

Effect of risperidone and olanzapine on reproductive hormones, psychopathology and sexual functioning in male patients with schizophrenia.

Konarzewska B, Wołczyński S, Szulc A, Galińska B, Popławska R, Waszkiewicz N.

Psychoneuroendocrinology. 2009 Jan;34(1):129-39. doi: 10.1016/j.psyneuen.2008.08.015. Epub 2008 Oct 5.

PMID:
18838228
16.

[Atypical antipsychotics and sexual dysfunction: five case-reports associated with risperidone].

Haefliger T, Bonsack C.

Encephale. 2006 Jan-Feb;32(1 Pt 1):97-105. French.

PMID:
16633296
17.

Plasma concentrations of estradiol in women suffering from schizophrenia treated with conventional versus atypical antipsychotics.

Bergemann N, Mundt C, Parzer P, Jannakos I, Nagl I, Salbach B, Klinga K, Runnebaum B, Resch F.

Schizophr Res. 2005 Mar 1;73(2-3):357-66.

PMID:
15653282
18.

[Decrease in mineral bone density in schizophrenic patients treated with 2nd generation antipsychotics].

Wyszogrodzka-Kucharska A, Rabe-Jabłońska J.

Psychiatr Pol. 2005 Nov-Dec;39(6):1173-84. Polish.

PMID:
16526183
19.

Effects of plasma magnesium and prolactin on quantitative ultrasound measurements of heel bone among schizophrenic patients.

Renn JH, Yang NP, Chou P.

BMC Musculoskelet Disord. 2010 Feb 17;11:35. doi: 10.1186/1471-2474-11-35.

20.

Antipsychotic-induced hyperprolactinaemia, hypogonadism and osteoporosis in the treatment of schizophrenia.

O'Keane V.

J Psychopharmacol. 2008 Mar;22(2 Suppl):70-5. doi: 10.1177/0269881107088439. Review.

PMID:
18477623
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk